PROWL › Markets explained › Science

FDA approves skin cancer vaccine by...?

This event asks whether the U.S. FDA will approve intismeran autogene (also called mRNA-4157 or V940), the individualized cancer therapy from Moderna and Merck, for any use by a set date. The market title says 'skin cancer vaccine', but the rules count an approval for any indication, not only melanoma. The three listed markets differ only in the cutoff date: June 30, September 30 and December 31, 2027.

Right now, the chance of yes by each date: June 30, 2027 14%, September 30, 2027 33%, December 31, 2027 62%.

MarketChance of yesDeadline
Skin cancer vaccine FDA approved by June 30, 2027?14.0%Jul 1, 2027, 3:59 UTC
Skin cancer vaccine FDA approved by September 30, 2027?33.0%Oct 1, 2027, 3:59 UTC
Skin cancer vaccine FDA approved by December 31, 2027?62.5%Jan 1, 2028, 4:59 UTC

Odds read from Polymarket at 22:18 UTC on Nov 21, 2026. $314K traded so far, $432 in the last 24 hours.

How this market resolves

Yes: The FDA approves intismeran autogene (an NDA or BLA approval letter, or an approved supplemental application) for any indication on or before the market's cutoff. Standard and accelerated approval both count. So does approval inside a combination regimen, for a narrower group of patients than the INTerpath-001 trial studied, or for a disease other than melanoma.

No: No qualifying FDA approval happens by the cutoff. The market also resolves No if the only FDA actions are things the rules exclude, such as a Complete Response Letter, a request for more data, a delayed decision date, or compassionate-use access.

When it really ends

The rules text gives December 31, 2027, 11:59 PM ET, which is 2028-01-01 04:59 UTC (ET is UTC-5 in winter). The rules text provided states only this date. For the other two markets, the June 30 and September 30, 2027 cutoffs come from their titles, assuming the same 11:59 PM ET time. That is 11:59 PM EDT (UTC-4), or 2027-07-01 03:59 UTC and 2027-10-01 03:59 UTC. In all three cases the endDate field in the data matches these moments.

What counts

  • A BLA or NDA approval letter for intismeran autogene, by any name (mRNA-4157, V940, or a later brand or generic name).
  • Approval for an indication other than melanoma.
  • Approval for a narrower patient group than the one studied in INTerpath-001.
  • Approval as part of a combination regimen.
  • Accelerated approval, approval with a REMS, or approval with post-marketing requirements or restricted distribution.

What does not count

  • A Complete Response Letter, or any other sign that the application cannot be approved as filed.
  • An FDA request for more information or studies, or an extension of the PDUFA decision date.
  • Compassionate use or expanded access only.
  • An Emergency Use Authorization without full approval.
  • Approval only for export or for use outside the United States, such as approval by a non-U.S. regulator.

Fine print people miss

What moves the price

Put a bot on this market

A PROWL bot reads the news around the clock, judges each post against these exact rules, and trades inside the limits you set. It starts in paper mode.

Questions people ask

Is there an FDA-approved skin cancer vaccine?

This market exists because the answer depends on approval of intismeran autogene (mRNA-4157/V940) by Moderna and Merck. It resolves Yes only if the FDA grants approval by the cutoff date. The rules text does not say whether that has happened.

What is intismeran autogene?

Per the rules, it is the individualized neoantigen therapy from Moderna and Merck tested in the Phase 3 INTerpath-001 trial (NCT05933577). It is also known as mRNA-4157 and V940.

Does the approval have to be for melanoma?

No. The rules say approval for any indication counts, including a narrower population than the trial studied and diseases other than melanoma.

What is the deadline for this market?

For the December market, it is December 31, 2027 at 11:59 PM ET, which is 2028-01-01 04:59 UTC. The June and September markets use the same time of day on June 30 and September 30, 2027.

Does accelerated approval count?

Yes. Both standard and accelerated approval qualify, as do approvals with a REMS or post-marketing requirements.

Does a Complete Response Letter or a delayed decision date count as approval?

No. A Complete Response Letter, an extended PDUFA date, a request for more information, expanded access, or an EUA without full approval does not count. Only a real FDA approval does.

More Science markets explained

Measles cases in U.S. in 2026?$8.4M tradedHuman moon landing in 2026?$2.0M tradedNew pandemic in 2026?$1.3M tradedOpenAI announces another Millennium Prize solution by...?$1.3M tradedWill the Doge-1 Lunar Mission launch by...?$1.2M tradedFDA approves Retatrutide this year?$599K tradedHow many SpaceX Starship launches reach space in 2026?$538K tradedPlague pandemic in 2026?$535K traded

Written from the market's own rules text on Nov 16, 2026. If the rules on Polymarket differ from this page, the rules on Polymarket govern.